
Commentary|Videos|March 16, 2026
Deescalation Therapies in Breast Cancer Treatment
Author(s)Natalie Berger, MD
Fact checked by: Paige Britt
New HER2+ breast cancer trials refine chemo and antibody use—cutting toxicity with de‑escalation, while escalating high‑risk patients with T‑DXd.
In an interview with Targeted Oncology, Natalie Berger, MD, hematologist and oncologist at the New York Presbyterian Medical Group, discusses the biggest real-world challenges in breast cancer treatment today.




























